Novartis AG ADR(NVS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 6:55 PM ET (Korea 9/12 07:55)
Full metrics table
| Index | - | P/E | 20.69 | EPS (ttm) | 6.63 | Insider Own | 0.01% | Shs Outstand | 1.83B | Perf Week | -15.9% |
| Market Cap | 251.08B | Forward P/E | 14.01 | EPS next Y | 11.34% | Insider Trans | - | Shs Float | 1.83B | Perf Month | -9.95% |
| Enterprise Value | 292.81B | PEG | 2.21 | EPS next Q | 2.25 | Inst Own | 7.49% | Short Float | 0.31% | Perf Quarter | -10.89% |
| Income | 12.76B | P/S | 4.58 | EPS this Y | -2.08% | Inst Trans | -0.21% | Short Ratio | 2.75 | Perf Half Y | -11.08% |
| Sales | 54.79B | P/B | 6.04 | EPS next 5Y | 6.34% | ROA | 11.27% | Short Interest | 5.63M | Perf YTD | -0.51% |
| Book/sh | 22.69 | P/C | 32.65 | EPS past 3/5Y | 31.4% 15.24% | ROE | 30.56% | 52W High | -19.54% ($170.46) | Perf Year | 7.41% |
| Cash/sh | 4.2 | P/FCF | 14.97 | Sales past 3/5Y | 9.03% 2.29% | ROIC | 15.82% | 52W Low | 12.82% ($121.57) | Perf 3Y | 46.06% |
| Dividend Est. | $4.43 (3.23%) | EV/EBITDA | 13.68 | EPS Y/Y TTM | -4.08% | Gross Margin | 74.08% | Volatility(W/M) | 1.63% 1.53% | Perf 5Y | 69.67% |
| Dividend TTM | 4.74 | EV/Sales | 5.34 | Sales Y/Y TTM | 2.33% | Oper. Margin | 29.58% | ATR (14) | 4.29 | Perf 10Y | 105.75% |
| Dividend Ex-Date | 2026/3/11 | Quick Ratio | 0.67 | EPS Q/Q | -18.54% | Profit Margin | 23.29% | RSI (14) | 31.5 | Recom | 2.5 |
| Dividend Gr. 3/5Y | 10.71% 8.17% | Current Ratio | 0.86 | Sales Q/Q | 0.97% | SMA20 | -10.51% ($153.27) | Beta | 0.43 | Target Price | $154.55 |
| Payout | 42.5% | Debt/Eq | 1.18 | Earnings | 2026/7/21 | SMA50 | -11.02% ($154.15) | Rel Volume | 1.15 | Prev Close | $137.48 |
| Employees | 75267 | LT Debt/Eq | 0.94 | EPS/Sales Surpr. | 10.95% 2.43% | SMA200 | -8.52% ($149.93) | Avg Volume(3M) | 2.05M | Price | $137.16 |
| IPO | 1996/11/7 | Option/Short | Yes/Yes | Trades | 21557 | Volume | 2,352,486 | Change | -0.23% |
Company
NVS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 A global large pharmaceutical company developing innovative medicines in oncology, cardiovascular, immunology, and neuroscience. It was established in 1996 through the merger of Ciba-Geigy and Sandoz, and is headquartered in Switzerland, with its U.S. stock market listing in the form of an American Depositary Receipt (ADR).
Over the past 1 year, roughly in the middle
20% below its 1-year high.
NVS makes money exceptionally well
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -2.1% this year.
Tap to view numbers
The price looks about right
Trading at 20.7 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +46.1% if bought 5 years ago.
Tap to view numbers
Dividends are paid consistently
Pays 3.23% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 7.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
EWL 0.14%
FLSW 0.13%
PPH 0.11%
MEDX 0.07%
EUDG 0.05%It ranks #4 in the industry
Based on market cap of $251B.
NVS $251B PER 20.7
LLY $1.1T PER 37.9
JNJ $640B PER 30.8
ABBV $454B PER 72.7
FAQ
What kind of company is NVS?
NVS belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of NVS?
The market cap of NVS is approximately $251.1B, ranking 58 within its sector.
Does NVS pay dividends?
NVS has a dividend yield of approximately 3.23%, with an annual dividend of $4.43.
What is the P/E ratio of NVS?
NVS has a P/E ratio of approximately 20.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for NVS?
NVS has recorded a 52-week high of $170.46 and a low of $121.57.
